The Experts below are selected from a list of 37470 Experts worldwide ranked by ideXlab platform
Morie A. Gertz - One of the best experts on this subject based on the ideXlab platform.
-
immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
Blood Cancer Journal, 2021Co-Authors: Hasib M Sidiqi, Morie A. GertzAbstract:Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to Therapy Delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.
-
Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
Blood Cancer Journal, 2018Co-Authors: Morie A. GertzAbstract:Immunoglobulin light chain amyloidosis (AL) should be considered in any patient that presents to a cancer care provider with nephrotic range proteinuria, heart failure with preserved ejection fraction, non-diabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to Therapy Delay is common, and it represents an error of diagnostic consideration. Algorithms will be provided on how to evaluate patients with suspected AL amyloid as well as how to manage patients referred from other medical specialties with biopsy-proven amyloid. An organized stepwise approach to the treatment of patients with light chain amyloidosis, including established and investigational therapies, will be reviewed.
Hasib M Sidiqi - One of the best experts on this subject based on the ideXlab platform.
-
immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
Blood Cancer Journal, 2021Co-Authors: Hasib M Sidiqi, Morie A. GertzAbstract:Immunoglobulin light chain amyloidosis (AL) commonly presents with nephrotic range proteinuria, heart failure with preserved ejection fraction, nondiabetic peripheral neuropathy, unexplained hepatomegaly or diarrhea, and should be considered in patients presenting with these symptoms. More importantly, patients being monitored for smoldering multiple myeloma and a monoclonal gammopathy of undetermined significance (MGUS) are at risk for developing AL amyloidosis. MGUS and myeloma patients that have atypical features, including unexplained weight loss; lower extremity edema, early satiety, and dyspnea on exertion should be considered at risk for light chain amyloidosis. Overlooking the diagnosis of light chain amyloidosis leading to Therapy Delay is common, and it represents an error of diagnostic consideration. Herein we provide a review of established and investigational treatments for patients with AL amyloidosis and provide algorithms for workup and management of these patients.
Steven Shochat - One of the best experts on this subject based on the ideXlab platform.
-
influence of radiation Therapy Delay on abdominal tumor recurrence in patients with favorable histology wilms tumor treated on nwts 3 and nwts 4 a report from the national wilms tumor study group
International Journal of Radiation Oncology Biology Physics, 2003Co-Authors: John A Kalapurakal, Sierra M Li, Norman E Breslow, Bruce J Beckwith, Roger M Macklis, Patrick R M Thomas, G J Dangio, Alfred De Lorimier, Panayotis P Kelalis, Steven ShochatAbstract:Abstract Purpose This study was undertaken to determine whether radiation Therapy (RT) Delay of ≥10 days had an adverse impact on abdominal tumor recurrence among children with favorable histology (FH) Wilms' tumor enrolled in National Wilms' Tumor Study (NWTS) 3 and 4. Methods and materials A total of 1226 patients with Stage II–IV FH tumors who received flank or abdominal RT in NWTS-3 and NWTS-4 were included in this analysis. Recurrent disease in the operative bed was classified as flank recurrence. Abdominal recurrence included all infradiaphragmatic tumor recurrences, including flank recurrences. This analysis included all flank/abdominal tumor recurrences, regardless of whether they might have been the initial or subsequent site of relapse. Based on the NWTS-1 results, RT Delay was analyzed in two categories: 0–9 days and ≥10 days. Results The mean RT Delay was 10.9 days; median Delay was 9 days (range: 1–277 days). The RT Delay was concentrated in a relatively narrow range of 8 to 12 days after nephrectomy in the majority of patients (59%). Univariate and multivariate analysis did not reveal RT Delay of ≥10 days to significantly influence flank and abdominal tumor recurrence rates in NWTS-3 or NWTS-4. The 8-year flank tumor recurrence rates for 0–9 days and 10+ days RT Delay were 1.9% and 1.2%, respectively ( p value=0.3). The 8-year abdominal tumor recurrence rates for 0–9 days and 10+ days RT Delay were 4.8% and 5.3%, respectively ( p value=0.7). Conclusions RT Delay of ≥10 days did not significantly influence flank or abdominal tumor recurrence rates among children with FH tumors treated on NWTS-3 and NWTS-4. However, we were unable to test for a meaningful difference, because of the concentration of RT Delay close to 10 days.
John A Kalapurakal - One of the best experts on this subject based on the ideXlab platform.
-
influence of radiation Therapy Delay on abdominal tumor recurrence in patients with favorable histology wilms tumor treated on nwts 3 and nwts 4 a report from the national wilms tumor study group
International Journal of Radiation Oncology Biology Physics, 2003Co-Authors: John A Kalapurakal, Sierra M Li, Norman E Breslow, Bruce J Beckwith, Roger M Macklis, Patrick R M Thomas, G J Dangio, Alfred De Lorimier, Panayotis P Kelalis, Steven ShochatAbstract:Abstract Purpose This study was undertaken to determine whether radiation Therapy (RT) Delay of ≥10 days had an adverse impact on abdominal tumor recurrence among children with favorable histology (FH) Wilms' tumor enrolled in National Wilms' Tumor Study (NWTS) 3 and 4. Methods and materials A total of 1226 patients with Stage II–IV FH tumors who received flank or abdominal RT in NWTS-3 and NWTS-4 were included in this analysis. Recurrent disease in the operative bed was classified as flank recurrence. Abdominal recurrence included all infradiaphragmatic tumor recurrences, including flank recurrences. This analysis included all flank/abdominal tumor recurrences, regardless of whether they might have been the initial or subsequent site of relapse. Based on the NWTS-1 results, RT Delay was analyzed in two categories: 0–9 days and ≥10 days. Results The mean RT Delay was 10.9 days; median Delay was 9 days (range: 1–277 days). The RT Delay was concentrated in a relatively narrow range of 8 to 12 days after nephrectomy in the majority of patients (59%). Univariate and multivariate analysis did not reveal RT Delay of ≥10 days to significantly influence flank and abdominal tumor recurrence rates in NWTS-3 or NWTS-4. The 8-year flank tumor recurrence rates for 0–9 days and 10+ days RT Delay were 1.9% and 1.2%, respectively ( p value=0.3). The 8-year abdominal tumor recurrence rates for 0–9 days and 10+ days RT Delay were 4.8% and 5.3%, respectively ( p value=0.7). Conclusions RT Delay of ≥10 days did not significantly influence flank or abdominal tumor recurrence rates among children with FH tumors treated on NWTS-3 and NWTS-4. However, we were unable to test for a meaningful difference, because of the concentration of RT Delay close to 10 days.
Roger M Macklis - One of the best experts on this subject based on the ideXlab platform.
-
influence of radiation Therapy Delay on abdominal tumor recurrence in patients with favorable histology wilms tumor treated on nwts 3 and nwts 4 a report from the national wilms tumor study group
International Journal of Radiation Oncology Biology Physics, 2003Co-Authors: John A Kalapurakal, Sierra M Li, Norman E Breslow, Bruce J Beckwith, Roger M Macklis, Patrick R M Thomas, G J Dangio, Alfred De Lorimier, Panayotis P Kelalis, Steven ShochatAbstract:Abstract Purpose This study was undertaken to determine whether radiation Therapy (RT) Delay of ≥10 days had an adverse impact on abdominal tumor recurrence among children with favorable histology (FH) Wilms' tumor enrolled in National Wilms' Tumor Study (NWTS) 3 and 4. Methods and materials A total of 1226 patients with Stage II–IV FH tumors who received flank or abdominal RT in NWTS-3 and NWTS-4 were included in this analysis. Recurrent disease in the operative bed was classified as flank recurrence. Abdominal recurrence included all infradiaphragmatic tumor recurrences, including flank recurrences. This analysis included all flank/abdominal tumor recurrences, regardless of whether they might have been the initial or subsequent site of relapse. Based on the NWTS-1 results, RT Delay was analyzed in two categories: 0–9 days and ≥10 days. Results The mean RT Delay was 10.9 days; median Delay was 9 days (range: 1–277 days). The RT Delay was concentrated in a relatively narrow range of 8 to 12 days after nephrectomy in the majority of patients (59%). Univariate and multivariate analysis did not reveal RT Delay of ≥10 days to significantly influence flank and abdominal tumor recurrence rates in NWTS-3 or NWTS-4. The 8-year flank tumor recurrence rates for 0–9 days and 10+ days RT Delay were 1.9% and 1.2%, respectively ( p value=0.3). The 8-year abdominal tumor recurrence rates for 0–9 days and 10+ days RT Delay were 4.8% and 5.3%, respectively ( p value=0.7). Conclusions RT Delay of ≥10 days did not significantly influence flank or abdominal tumor recurrence rates among children with FH tumors treated on NWTS-3 and NWTS-4. However, we were unable to test for a meaningful difference, because of the concentration of RT Delay close to 10 days.